| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $241.5M-4.2% | $252.2M+0.3% | $251.4M+12.9% | $222.7M |
| Cost of revenue exclusive of amortization | $38.0M-6.7% | $40.7M+17.1% | $34.7M+34.3% | $25.9M |
| Amortization | $20.3M+44.4% | $14.0M+10.3% | $12.7M-24.0% | $16.8M |
| Gross profit | $183.3M-7.2% | $197.5M-3.2% | $203.9M+13.3% | $180.0M |
| Sales and marketing | $81.6M-2.6% | $83.8M-11.3% | $94.5M+5.5% | $89.6M |
| Product development | $34.8M-4.8% | $36.5M-14.0% | $42.4M+21.6% | $34.9M |
| General and administrative | $51.6M+4.8% | $49.3M-16.3% | $58.9M+14.2% | $51.6M |
| Depreciation and amortization | $35.8M-4.8% | $37.6M-3.6% | $39.0M-2.8% | $40.1M |
| Transaction, integration, and restructuring expenses | $7.6M-37.6% | $12.2M+6.4% | $11.5M+45.6% | $7.9M |
| Goodwill impairment | $196.1M-71.5% | $688.9M+139.7% | $287.4M | $0 |
| Total operating expenses | $407.5M-55.1% | $908.3M+70.2% | $533.7M+138.2% | $224.1M |
| Loss from operations | -$224.3M+68.4% | -$710.8M-115.5% | -$329.8M-648.8% | -$44.0M |
| Interest income | $7.0M-52.4% | $14.6M+6.9% | $13.6M+389.6% | $2.8M |
| Interest expense | -$11.3M+23.9% | -$14.8M+2.4% | -$15.2M-35.7% | -$11.2M |
| Gain on remeasurement of TRA liability | $21.7M-71.8% | $76.9M+227.7% | $23.5M+141.5% | $9.7M |
| Loss on partial extinguishment of debt | -$507K | $0 | $0 | — |
| Other (expense) income, net | -$1.8M-549.4% | $411K+241.2% | -$291K-133.8% | $862K |
| Total other income, net | $15.0M-80.5% | $77.1M+256.5% | $21.6M+898.2% | $2.2M |
| Loss before income taxes | -$209.3M+67.0% | -$633.7M-105.6% | -$308.2M-635.9% | -$41.9M |
| Benefit from income taxes | $10.0M-76.5% | $42.3M+128.0% | $18.6M+4.8% | $17.7M |
| Net loss | -$199.3M+66.3% | -$591.4M-104.2% | -$289.6M-1097.8% | -$24.2M |
| Less: Net loss attributable to noncontrolling interests | -$60.4M+66.1% | -$178.3M-104.4% | -$87.2M-414.5% | -$17.0M |
| Net loss attributable to Definitive Healthcare Corp. | -$138.9M+66.4% | -$413.1M-104.1% | -$202.4M-2702.4% | -$7.2M |
| Basic | $106.65B-8.6% | $116.64B+3.4% | $112.76B+161092195814.3% | -$70 |
| Diluted | $106.65B-8.6% | $116.64B+3.4% | $112.76B+161092195814.3% | -$70 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.